Objectives

• Assess the pharmacokinetics of sirolimus after Ultimaster implantation 
• Evaluate the systemic concentration and potential toxicity of sirolimus
• Assess endothelial function
• Investigate the safety and tolerability profile of Ultimaster, along with therapeutic outcomes
  

Stojkovic S et al. Fundam Clin Pharmacol 2014;29:95–105.

Study design

PK, pharmacokinetics.
Stojkovic S et al. Fundam Clin Pharmacol 2014;29:95–105; Data on file at Terumo Europe

Other findings

• 6 months: 
• Endothelial function well preserved
• In-stent late loss: 0.10±0.28 mm
• Up to 12 months:
• No signs of sirolimus toxicity or other safety concerns

Stojkovic S et al. Fundam Clin Pharmacol 2014;29:95–105.